Author(s): Pelekanou A, Kanni T, Savva A, Mouktaroudi M, Raftogiannis M, Kotsaki A, Giamarellos-Bourboulis EJ
OBJECTIVE: To evaluate the long-term efficacy of etanercept for the management of hidradenitis suppurativa.
METHODS: Analysis was based on the long-term follow-up (weeks 24-144) of 10 patients enrolled in a prospective open-label phase II study; etanercept was initially administered subcutaneously 50 mg once weekly for 12 weeks in 10 patients. Disease recurrence and the need to restart etanercept were recorded.
RESULTS: Three patients did not report any disease recurrence. A second course of treatment with etanercept was needed in seven patients. Favourable responses were found in five; two patients failed treatment.
CONCLUSIONS: The first treatment course achieved long-term disease remission in almost one-third of patients. The remaining needed a second treatment course but even in that case, their disease severity at restart was significantly lower compared with baseline.
Dermatology Journal and/or Publisher
Journal Name: Experimental dermatology
Journal Abbreviation: Exp. Dermatol.
Journal Date Published: 2010-06-29
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/19758320
Lasted Revision: 2015-11-19
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).